Analysts Set Expectations for Kineta, Inc.’s Q2 2023 Earnings (NASDAQ:KA)

Posted by on May 22nd, 2023

Kineta, Inc. (NASDAQ:KA – Get Rating) – Research analysts at HC Wainwright dropped their Q2 2023 earnings estimates for shares of Kineta in a research note issued to investors on Thursday, May 18th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.72) per share for the quarter, down from their previous estimate of ($0.68). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Kineta’s current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Kineta’s Q3 2023 earnings at ($0.49) EPS, Q4 2023 earnings at ($0.40) EPS, FY2023 earnings at ($2.19) EPS, Q1 2024 earnings at ($0.41) EPS, Q2 2024 earnings at ($0.42) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.45) EPS and FY2024 earnings at ($1.72) EPS.

Kineta Price Performance

Kineta stock opened at $3.04 on Monday. The company has a fifty day moving average of $3.81. Kineta has a 1 year low of $2.87 and a 1 year high of $15.54. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.80 and a current ratio of 0.80.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new position in Kineta in the 1st quarter valued at about $34,000. CIBC Asset Management Inc purchased a new stake in Kineta during the first quarter worth approximately $45,000. Renaissance Technologies LLC purchased a new stake in Kineta during the fourth quarter worth approximately $111,000. Finally, Artal Group S.A. purchased a new stake in Kineta during the fourth quarter worth approximately $197,000. Hedge funds and other institutional investors own 22.01% of the company’s stock.

About Kineta

(Get Rating)

Kineta, Inc is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. Its immuno-oncology focused platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance. The company was founded by Shawn P. Iadonato and Charles L.

See Also

Earnings History and Estimates for Kineta (NASDAQ:KA)

Receive News & Ratings for Kineta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kineta and related companies with MarketBeat.com's FREE daily email newsletter.